Skip to main content
MHRP

Main navigation

  • About Us toggle dropdown
    • Our Team
      • Leadership
      • Researchers
      • Global Health
      • Labs
    • WRAIR
    • HJF
    • Impact
    • Publications
      • Publication Supplements
    • Fact Sheets
    • Newsletters
    • Contact Us
  • PEPFAR toggle dropdown
    • Kenya
    • Nigeria
    • Tanzania
    • Uganda
    • PEPFAR Research
      • African Cohort Study (AFRICOS)
  • HIV Research toggle dropdown
    • Vaccine Research
      • RV144
      • Vaccine Approaches
      • ALF Adjuvants
      • Other Vaccines
    • Acute HIV and Cure Research
      • RV217
      • RV254
      • HIV Cure
    • Epidemiology and Threat Assessment
      • Cohorts and Other Observational Studies
      • Clinical Trials
  • Global Research toggle dropdown
    • Germany
    • Jordan
    • Kenya
    • Mozambique
    • Nigeria
    • Tanzania
    • Thailand
    • Uganda
  • News
  • Careers toggle dropdown
    • Benefits & Culture
    • Current Opportunities
    • International Careers
    • Meet the Team
  • Search
Epidemiology and Threat Assessment

Clinical Trials


Sub Menu

Cohorts and Other Observational Studies

Related Content

News 4.11.2022

Trial in Thailand Evaluates Gonococcal Vaccine

MHRP's Department of Epidemiology and Threat Assessment (DETA) conducts observational and epidemiologic studies that facilitate site capacity building and community engagement. This research infrastructure is leveraged to support a growing portfolio of interventional studies that enroll military and civilian populations, with an emphasis on the testing of novel strategies to prevent HIV and other sexually transmitted infections (STIs).

KISS Study

The KISS study is a prospective trial to assess the acceptability and efficacy of a behavioral intervention to reduce the risk of HIV and other STIs in a population of Army personnel and medical beneficiaries. All participants receive the standard STI prevention counseling that is routinely provided by military medical treatment facilities. In addition, participants in the intervention arm receive an evidence-based, gender-specific, interactive educational intervention (Knocking out Infections through Safer sex and Screening [KISS]) and follow-up communications via text and telephone to reinforce concepts learned during the in-person educational session. Changes in sexual behaviors are evaluated via behavioral surveys at enrollment, six, and twelve months. Participants also undergo screening for gonorrhea and chlamydia at these visits. 

MAGI (RV564)

The multisite, multinational Meningococcal vaccine Against Gonococcal Infection (MAGI) study is a phase II randomized, observer-blind, placebo-controlled study to assess the efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection. Participants will be randomized to receive either the Bexsero vaccine or placebo, administered as two intramuscular injections, and followed for safety, clinical, and laboratory assessments. It will enroll participants in the United States and Thailand with standardized study procedures across all study sites. Two MHRP-collaborating sites in Thailand are expected to enroll approximately 1,000 participants who are at risk for gonorrhea. 

Sign Up For Our Newsletter

WRAIR WRAIR
HJF HJF
MHRP U.S. Military HIV Research Program MHRP U.S. Military HIV Research Program

Social Navigation

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

Footer

  • Accessibility
  • Disclaimers
  • Privacy
  • Contact MHRP

©2022 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

This site was created by HJF. The appearance of U.S. Department of Defense visual information does not imply or constitute DoD endorsement.